Loading...
Loading...
TSBX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.5M |
| Operating Expense | 18.4M |
| Operating I/L | -18.4M |
| Other Income/Expense | 0.5M |
| Interest Income | 0.0M |
| Pretax | -17.8M |
| Income Tax Expense | -0.8M |
| Net Income/Loss | -17.0M |
Turnstone Biologics Corp. is a clinical stage biotechnology company specializing in developing innovative medicines for the treatment and cure of solid tumors. The company's lead product, TIDAL-01, is currently in Phase 1 clinical trials for breast cancer, colorectal cancer, uveal melanoma, and an investigator sponsored trial for cutaneous and non-cutaneous melanomas. Additionally, Turnstone Biologics Corp. is advancing TIDAL-02 through preclinical development for the treatment of solid tumors.
